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Background: The expression of novel oncogenic kinase (NOK), a member of the protein tyrosine kinase (PTK)
family, has been observed in several human malignancies including non-small cell lung cancer (NSCLC). However,
the clinic relevance of NOK expression in NSCLC remains unclear.
Methods: In this study, NOK expression in tumor cells was assessed using immunohistochemical methods in 191
patients with resected NSCLC. The association of NOK expression with clinicopathological parameters, including the
Ki-67 labeling index (LI), was also evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models
were used to estimate the effect of NOK expression on survival.
Results: Data showed that NOK was expressed in 75.4% and 14.1% of cancer lesions and corresponding adjacent
non-cancerous tissue, respectively. Out of all the clinicopathological factors analyzed, NOK expression was
significantly correlated with the grade of tumor differentiation (P = 0.035), pTNM stage (P = 0.020), lymphatic
metastasis (P = 0.005) and high Ki-67 LI (P < 0.001). NOK positive NSCLC patients had a significantly shorter survival
time (P = 0.004, Log-rank test) and the prognostic significance of NOK expression was apparent in squamous cell
carcinoma patients (P = 0.022). Multivariate analysis indicated that NOK expression may be an independent
prognostic factor in NSCLC (hazard ratio [HR], 1.731; P = 0.043).
Conclusions: Our results indicate that NOK expression is of clinical significance and can serve as a prognostic
biomarker in NSCLC.
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Lung cancer is the leading cause of cancer-related death
worldwide. Non-small cell lung cancer (NSCLC) accounts
for most cases of lung cancer, however, the long-term sur-
vival rate of NSCLC patients remains unsatisfactory. A
majority of NSCLC patients die from recurrent disease
and distant metastases even after undergoing curative sur-
gical resection [1-3]. There is an urgent need to identify
new prognostic markers that can facilitate a better assess-
ment of the survival probabilities and optimized therapies
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unless otherwise stated.Novel oncogenic kinase (NOK), also known as a puta-
tive serine/threonine and tyrosine receptor protein kin-
ase (STYK) 1, was identified as a new member of the
protein tyrosine kinase (PTK) family by Liu et al. [4,5]. It
has a single putative transmembrane domain and an
intracellular domain possessing tyrosine kinase activity
but lacks an extracellular domain for binding specific li-
gands. Previous studies showed that NOK shares hom-
ology with members of the platelet-derived growth factor/
fibroblast growth factor receptor superfamily and the
overexpression of NOK in BaF3 cells induced tumorigen-
esis and metastasis in nude mice [5,6]. Furthermore, over-
expression of NOK was detected in acute leukemia,
ovarian cancer, breast cancer and lung cancer, but the
prognostic role of NOK was not found [7-11]. A recent
report also indicates NOK is functionally involved intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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is related with epithelial-to-mesenchymal transition
(EMT) [12].
To study the clinicopathologic features and prognostic
implications of NOK expression in patients with NSCLC,
we investigated the expression of NOK in NSCLC by im-
munohistochemical staining and assessed the relationships
between NOK expression and clinical parameters.
Methods
Patients and tissue samples
Paraffin-embedded tissue specimens from 191 patients
with confirmed NSCLC, collected from 2007 to 2010,
were analyzed from an archived thoracic oncology tissue
repository at the Department of Thoracic Surgery of
Tangdu Hospital. Patients who received preoperative
chemotherapy, radiotherapy or epidermal growth factor
receptor (EGFR)-targeted therapy were excluded from
this study. Detailed information was obtained from the
medical records of the enrolled patients in a computerized
registry database including patient age, gender, smoking
history, clinical manifestation, surgical method, tumor sta-
tus, histological differentiation, nodal status and follow-up
information. Follow-up lasted through 30 October, 2012,
with a median follow-up period of 39 months for living
patients (range, 23-64months). The day of surgery was
considered as the starting day for estimating postoperative
survival time. Histological classification of tumors was
reviewed by pathologists and based on the World Health
Organization criteria. All tumors were staged according to
the pathological tumor/node/metastasis (pTNM) classifi-
cation (7th edition) of the International Union against
Cancer [13]. The study protocol was approved by the Re-
gional Ethics Committee for Clinical Research of the
Fourth Military Medical University. All patients provided
written informed consent for use of their medical records
and tissue specimens for research purposes.
Immunohistochemistry
Tissue blocks were cut into 5-μm sections and mounted
on silane-coated slides. The slides were then dewaxed in
xylene and rehydrated through a graded series of ethanol
solution. Endogenous peroxidase activity was blocked by
immersing the slides in a solution of 3% hydrogen per-
oxide in methanol for 30 min. Antigen retrieval was per-
formed by microwaving sections in 10 mM citrate buffer
(pH 6.0) at 95°C for 20 min. To reduce nonspecific bind-
ing, slides were blocked with goat serum for 30 min.
Then, the sections were incubated in a humidified cham-
ber at 4°C overnight with primary anti-NOK (diluted
1:100, Abcam, USA) or anti-Ki-67 (diluted 1:50, Thermo,
USA) antibodies. After washing three times in PBS (phos-
phate-buffered saline), the slides were incubated for 60 min
with a labeled polymer En Vision+. Peroxidase activity wasvisualized with the DAB Elite kit (Dako, Denmark), and the
slides were counterstained with hematoxylin. To confirm
the specificity of the immunostaining, negative controls
were obtained by replacing the primary antibody with PBS.
Evaluation of immunohistochemical staining
Five randomly fields from each section were viewed
under a light microscope (Leica DM4000B, Germany)
at × 400 magnification. The expression of NOK was scored
by multiplication of the percentage of positive tumor cells
and the staining intensity. Initially, the percentage of posi-
tive cells was scored as 0 (0%), 1 (1-10%), 2 (11-50%), and
3 (51-100%). Thereafter, intensity of staining was scored as
follows: 0 (negative), 1 (weakly positive), 2 (moderately
positive), and 3 (strongly positive). By ROC analyses, the
case with a final scores ≥ 3 was classified as positive
(Sensitivity 70.7, Specificity 90.6). For Ki-67, the ex-
pression of Ki-67 was assessed based on the labeling
index (LI) determined by counting 500–1000 tumor
cells randomly selected in a high-power field. The me-
dian value of positive tumor cells was 31% in the current
series, therefore, we defined tumors with ≥31% of Ki-67 as
high Ki-67.
All slides were assessed by 3 independent investigators
who were blinded to the clinical features and outcomes.
The final immunohistochemical staining score reported
is the average of the scores from the three investigators.
Statistical analysis
Associations between NOK expression and clinicopatho-
logical parameters were evaluated using the χ2-test. Sur-
vival was examined using the Kaplan-Meier method, and
the significance of the difference was evaluated using the
log-rank test. Correlation analyses of the survival time
and various clinicopathological variables were performed
by univariate and multivariate analyses using the Cox re-
gression model. P < 0.05 were considered to be statisti-
cally significant. All analyses were performed with SPSS
18.0 software (SPSS, Inc., Chicago, IL).
Results
Patient characteristics
The clinicopathologic characteristics of the patients are
summarized in Table 1. There were 37 female and 154
male patients with a median age of 61 years (range, 28–
81 years). The patients were diagnosed with squamous
cell carcinoma (SCC; n = 98, 51.3%) and adenocarcinoma
(ADC; n = 93, 48.7%). Histopathologic diagnosis included:
well differentiation-42 (22.0%), moderately differentiation-
98 (51.3%), and poorly differentiation-51 (26.7%) tumors.
Postoperative staging evaluation demonstrated stage I dis-
ease in 47 patients, stage II disease in 81 patients, stage III
disease in 60 patients, and stage IV disease in 3 patients.
Table 1 Association between NOK expressions and




Positive (%) Negative (%) P-value*
Sex
Male 154 114 (74.0) 40 (26.0) 0.371
Female 37 30 (81.1) 7 (18.9)
Age
<60 90 70 (77.8) 20 (22.2) 0.470
≥60 101 74 (73.3) 27 (26.7)
Smoking history
Smoker 133 100 33 0.618
Non-smoker 58 42 16
Differentiation
Well + moderately 140 100 (71.4) 40 (28.6) 0.035
Poorly 51 44 (86.3) 7 (13.7)
Histological type
Squamous 98 71 (72.4) 27 (27.6) 0.332
Adenocarcinoma 93 73 (78.5) 20 (21.5)
pT factor
T1–2 148 110 (74.3) 38 (25.7) 0.525
T3–4 43 34 (79.1) 9 (20.0)
pN factor
N0 88 58 (65.9) 30 (34.1) 0.005
N1–2 103 86 (83.5) 17 (16.5)
pTNM stage
I-II 128 90 (70.3) 38 (29.7) 0.020
III-IV 63 54 (85.7) 9 (14.3)
Ki-67 labeling index
<31 94 57 (60.6) 37 (39.4) <0.001
≥31 97 89 (91.8) 8 (8.2)
*P-value of χ2-test are shown.
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clinicopathological parameters
Overall, 75.4% (144/191) tumor sections were classified
as NOK positive while 14.1% (27/191) corresponding ad-
jacent non-cancerous tissue sections were classified as
NOK positive. Positive staining was mainly located in
the cytoplasm (Figure 1).
In order to evaluate the role of NOK in NSCLC, we
investigated whether NOK expression was associated
with any of the clinicopathological variables (Table 1).
The results showed that NOK expression was signifi-
cantly associated with differentiation (P = 0.035), pN
factor (P = 0.005), pTNM stage (P = 0.020) and Ki-67
labeling index (P < 0.001). No significant relationship was
noted between NOK expression and sex (P = 0.371), age(P = 0.470), smoking history (P = 0.618), histological type
(P = 0.332), and pT factor (P = 0.525).
Relationship between NOK expression and survival in
NSCLC patients
To investigate the relationship between NOK expression
and the clinical outcome of NSCLC patients, the correl-
ation between patient survival and NOK expression sta-
tus was analyzed. Patients with NOK positive expression
had a significantly worse prognosis than those with NOK
negative expression (P = 0.004, Figure 2A). The median
survival time of patients with NOK-positive NSCLC
(n = 144) was 38 months (95% confidence interval [CI] =
26-50 months) and the mean survival time was 34 months
(95% CI = 30-39 months), whereas the median survival
time of patients with NOK-negative NSCLC (n = 47) had
not yet been reached and the mean survival time was
48 months (95% CI = 43-54 months). Among other factors
such as patient age, sex, smoking history, tumor histo-
logical type, grade of tumor differentiation and pTNM
stage, only the pTNM stage and grade of tumor differenti-
ation were significantly associated with patient survival.
The median survival time of patients with pTNM I/II tu-
mors (n = 128) was 55 months (95% CI was not reached),
whereas the median survival time of those with TNM III/
IV tumors (n = 63) was 14 months (95% CI = 7–21
months; P < 0.001, Figure 2B). Patients with well or mod-
erately differentiated tumors (n = 140, median survival
time was not reached) had a longer survival time than
those with poorly differentiated tumors (n = 51, me-
dian survival time = 19 months, 95% CI = 11-27 months;
P < 0.001).
Then, the patients were divided into the SCC and
ADC groups. The median survival time of patients with
NOK positive SCC (n = 71) was 23 months (95% CI =
12-34 months), whereas the median survival time of
those with NOK negative SCC (n = 27) was 51 months
(95% CI was not reached). SCC patients with NOK posi-
tive expression had a significantly worse prognosis than
those with NOK negative expression (P = 0.022, Figure 2C).
By contrast, the median and mean survival time of patients
with NOK-positive ADC (n = 73) was 43 months (95%
CI = 35-50 months) and 37 months (95% CI = 30-43
months), respectively, whereas the mean survival time
of those with NOK-negative ADC (n = 20) was 50 months
(95% CI = 42-57 months). There were no significant differ-
ence in the survival rate with respect to NOK expression
among ADC patients (P = 0.054; Figure 2D).
In order to investigate the relationship between NOK
expression and the clinical outcome of NSCLC patients
according to the different stage, we divided patients into
the pTNM I/II and pTNM III/IV groups. Among pa-
tients with I/II-stage tumors, the median and mean sur-
vival time of patients with NOK-positive tumors (n = 90)
Figure 1 Expression of NOK and Ki-67 in NSCLC. (A) Positive NOK staining in SCC. (B) Positive NOK staining in ADC. (C) Positive NOK staining
in corresponding adjacent non-cancerous tissue. (D) Positive Ki-67 staining in NSCLC. (E) Absence of NOK staining in NSCLC. (F) Absence of NOK
staining in corresponding adjacent non-cancerous tissue.
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(95% CI = 34-45 months), respectively, whereas the mean
survival time of those with NOK-negative tumors (n = 38)
was 51 months (95% CI = 45-57 months). There were no
significant difference in the survival rate with respect to
NOK expression (P = 0.061, Figure 2E). Among patients
with III/IV-stage tumors, the median survival time of
NOK positive patients (n = 54) was 12 months (95% CI =
7-17 months), whereas that of NOK negative patients
(n = 9) was 40 months (95% CI = 17-63 months). There
were no significant difference in the survival rate with
respect to NOK expression (P = 0.144, Figure 2F).
To further assess whether NOK expression represents
a prognostic parameter in patients with NSCLC, regres-
sion analysis using the Cox’s proportional hazards model
was performed. The covariate parameters included sev-
eral clinicopathological factors in addition to NOK, as
shown in Table 2. In univariate analysis, factors includingNOK expression, pTNM stage and grade of differentiation
showed a significantly higher hazard ratio for a poor prog-
nosis. Moreover, multivariate analysis was carried out
using the significant factors observed in univariate ana-
lysis. The results showed that, besides the TNM stage and
grade of differentiation, NOK expression was an inde-
pendent prognostic factor (P = 0.043, Table 2). These re-
sults strongly indicated that the NOK expression in
NSCLC patients is closely related to a poor prognosis.
Discussion
PTKs are important regulators of intracellular signal-
transduction pathways mediating development and multi-
cellular communication in metazoans. Their activity is
normally tightly controlled and regulated. In contrast,
alterations in the expression of various PTKs, in their
activation, and in the signaling molecules lying down-
stream of the receptors play important roles in the
Figure 2 Kaplan-Meier survival analysis for NSCLC patients. The P-value was determined using the log-rank test. (A) Comparison of the
overall survival (OS) between NOK negative and NOK positive NSCLC patients. (B) Comparison of the OS between pTNM I/II and pTNM III/IV
patients. (C) Comparison of the OS between NOK negative and NOK positive SCC patients. (D) Comparison of the OS between NOK negative
and NOK positive ADC patients. (E) Comparison of the OS between NOK negative and NOK positive pTNM I/II patients. (F) Comparison of
the OS between NOK negative and NOK positive pTNM III/IV patients.
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been associated with poor prognosis and is a predictor
of metastasis in NSCLCs [16]. Some PTKs, such as
EGFR and human epidermal growth factor receptor
(HER)2, play important roles in lung cancer and have
emerged as targets of new drug therapies [17-19]. As a
novel member of the PTK family, the clinical relevance
of NOK with NSCLC warrants evaluation.
In this study, we performed immunohistochemical analysis
of surgically resected NSCLC specimens to investigate NOK
expression in clinical samples. NOK protein was found to be
mainly localized in the cytoplasm. Immunohistochemicalanalysis revealed that 75.4% (144/191) of the tumor sections
analyzed were positive for NOK protein expression, while
14.1% (27/191) of corresponding adjacent non-cancerous tis-
sue were NOK-positive. In contrast to our results, Amachika
T et al. reported NOK mRNA was detected in 97.6% (40/41)
of lung cancer tissues [8]. The differences in the detection
methods and sample sizes might account for these differ-
ences. However, both the previous study and our analyses
showed that NOK expression in cancerous tissues is signifi-
cantly higher, compared to that in non-cancerous tissues.
These data suggest that NOK may be a new diagnostic tool
or biomarker for lung cancer. Subsequently, we found that
Table 2 Cox proportional hazards model analysis of variables affecting survival in NSCLC patients
Variables Categories Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age (years) ≥60/<60 1.330 (0.88-2.01) 0.178
Sex Male/female 0.835 (0.51-1.37) 0.473
Smoking history Smoking/Non-smoking 0.887 (0.58-1.37) 0.588
Histological type Squamous/adenocarcinoma 1.341 (0.89-2.02) 0.160
Grade of differentiation Poor/well + moderate 2.578 (1.70-3.90) <0.001 1.814 (1.19-2.78) 0.006
pTNM stage I/II/ III/IV 2.331 (1.79-3.05) <0.001 2.132 (1.61-2.82) <0.001
NOK expression Positive/negative 2.121 (1.25-3.59) 0.005 1.731 (1.02-2.94) 0.043
HR, hazard ratio; CI, confidence interval.
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some clinical parameters, such as the pN factor and pTNM
stage. These findings indicate that NOK may play an import
role in the metastasis of NSCLC. Recently, Li J et al. reported
that NOK forms complexes with both Akt and GSK-3β and
that this complex formation enhanced the phosphorylation
of GSK-3β [12]. Indeed, phosphorylated-GSK-3β expression
is frequently associated with EMT (epithelial-mesenchymal
transition), which promotes the dissemination of cancer cells
from primary tumors [20-22]. Our results are consistent
with those of the report from Li J. et al. [12], in that they
support a role for NOK in promoting metastases of NSCLC.
This study is the first, to our knowledge, to indicate an
association between NOK-positivity in NSCLC patients
and poor prognosis and to suggest that NOK expression
may be an independent prognostic factor of NSCLC pa-
tients. Furthermore, the prognostic significance of NOK
expression was apparent in SCC patients, while the dif-
ference in the survival rate with respect to NOK expres-
sion among ADC patients was not significant. Further
studies, in a larger cohort of patients with lung ADC,
are needed to determine whether NOK expression is a
predictor of poor prognosis in lung ADC patients. We
also investigated whether NOK expression was associ-
ated with prognosis in early stage NSCLC patients. The
results did not show apparent prognostic significance of
NOK expression in early stage patients as well as in late
stage patients. The basis of the relationship between NOK
expression and poor prognosis needs further evaluation.
We hypothesize that NOK expression may be related to
cancer cell proliferation and metastasis. Liu L et al. re-
ported that NOK-expressing tumor cells could promptly
invade and spread to various organs and form metastatic
foci, eventually leading to the rapid death of animals [5].
Li YH et al. reported that NOK is involved in the activa-
tion of the intracellular RAS/ mitogen-activated protein
kinase (MAPK) signaling pathway [23]. MAPK signaling
pathways have been implicated in the pathogenesis of a
variety of human cancers, including lung cancer [24,25].
Our previous studies indicated that NOK gene expressioncould improve the proliferation and invasion capabilities
of human lung adenocarcinoma cells [26,27]. The results
of the current study also demonstrate a probable relation-
ship between NOK expression and a high Ki-67 LI in
NSCLC patients. All of the above mentioned data may, in
part, account for the association between NOK expression
and poor prognosis in NSCLC.
There were some shortcomings present in this study.
Due to the limitations of sample size and follow-up, the
median survival time in many groups could not be ob-
tained. To respond the patient's survival, we listed the
mean survival time, which was failed to accurately re-
spond the patient’s survival as the median survival time.
In addition, this study did not investigate the relation-
ship between the expression level of NOK gene and the
pathogenesis of lung cancer, which was very important
for a biomarker validation. To compensate for these
shortcomings, we intend to carry out further multi-
center clinical studies, expand the sample size and en-
rich the means of detection.
Recently, EGFR- tyrosine kinase inhibitors (TKIs) and
ALK inhibitors have been used widely in clinical settings
as standard cancer therapies, and PTK-targeted therapies
have demonstrated clinical success in the treatment of
NSCLC [28,29]. Furthermore, a study by Ding X et al.
showed that NOK was co-localized with EGFR in endo-
somes and that it participates in a post-internalization
step of EGFR [30]. Taken together with the results in
this study, we believe that NOK might be a potential
drug therapy target for NSCLC patients. However, the
mechanism underlying the promotion of NSCLC by
NOK needs to be examined further.
Conclusions
We showed that a high proportion of NSCLCs express
NOK and that NOK expression is significantly associ-
ated with grade of tumor differentiation, pTNM stage,
and lymphatic metastasis. Moreover, our study is the
first to indicate a role for NOK as an independent factor
predictive of poor prognosis in NSCLCs.
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